Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma

  • Cancer Res. 2022 Jul 5;82(13):2403-2416. doi: 10.1158/0008-5472.CAN-21-2352.
Shawn M Davidson  1  2  3 ,  Daniel R Schmidt  #  1  3  4 ,  Julia E Heyman  #  1 ,  James P O'Brien  #  1 ,  Amy C Liu  #  1 ,  William J Israelsen  1  2 ,  Talya L Dayton  1  2 ,  Raghav Sehgal  5 ,  Roderick T Bronson  1 ,  Elizaveta Freinkman  6 ,  Howard H Mak  1 ,  Giuseppe Nicolò Fanelli  7  8 ,  Scott Malstrom  1 ,  Gary Bellinger  1  4 ,  Arkaitz Carracedo  4 ,  Pier Paolo Pandolfi  4 ,  Kevin D Courtney  9 ,  Abhishek Jha  5 ,  Ronald A DePinho  9 ,  James W Horner  9 ,  Craig J Thomas  10 ,  Lewis C Cantley  4  7 ,  Massimo Loda  7  9 ,  Matthew G Vander Heiden  1  2  3  9
Affiliations
  • 1. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • 2. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • 3. Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
  • 4. Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • 5. Elucidata, Cambridge, Massachusetts.
  • 6. Whitehead Institute, Cambridge, Massachusetts.
  • 7. Weill Cornell Medical College, New York, New York.
  • 8. Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • 9. Dana-Farber Cancer Institute, Boston, Massachusetts.
  • 10. National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland.
  • # Contributed equally.
PMID: 35584006 DOI: 10.1158/0008-5472.CAN-21-2352
Abstract

Differential expression of PKM1 and PKM2 impacts prostate tumorigenesis and suggests a potential therapeutic vulnerability in prostate Cancer.

Products